At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development; Millennium Pharmaceuticals
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC; Millennium Pharmaceuticals
- Class Antithrombotics; Indazoles; Organic chemicals
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 21 Mar 2002 COR Therapeutics has been acquired by, and integrated into, Millennium Pharmaceuticals
- 15 Sep 1999 Preclinical development for Thrombosis in USA (Unknown route)